Entries by CAPTIS

Landos Biopharma completes £49.7m series B financing

The financing was co-led by RTW Investments and Perceptive Advisors (Perceptive Xontogeny Venture Fund and Perceptive Life Sciences Fund), and joined by additional new investors, including Osage University The post Landos Biopharma completes £49.7m series B financing appeared first on Pharmaceutical Business review.

Janssen gets EC approval for two new indications of Imbruvica

The approval has been granted for the use of ibrutinib in combination with obinutuzumab in adult patients with previously untreated chronic lymphocytic leukaemia (CLL), as well as the The post Janssen gets EC approval for two new indications of Imbruvica appeared first on Pharmaceutical Business review.

Eidos Therapeutics confirms receipt of non-binding proposal from BridgeBio Pharma to acquire shares

BridgeBio currently owns, through its wholly-owned subsidiary, BridgeBio Pharma LLC, approximately 66.6% of the outstanding shares of the Company’s common stock. According to the terms of the Proposal, The post Eidos Therapeutics confirms receipt of non-binding proposal from BridgeBio Pharma to acquire shares appeared first on Pharmaceutical Business review.

Ascletis opens Clinical Development Shanghai Center

Ascletis’ Clinical Development Shanghai Center is at the heart of Shanghai, located at Jing’an Kerry Centre near Nanjing West Road. The opening ceremony was held on Aug 11, The post Ascletis opens Clinical Development Shanghai Center appeared first on Pharmaceutical Business review.